Jones Financial Companies Lllp Sells 194 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Jones Financial Companies Lllp trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 24.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 593 shares of the company’s stock after selling 194 shares during the period. Jones Financial Companies Lllp’s holdings in IDEXX Laboratories were worth $245,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of IDXX. FSA Wealth Management LLC purchased a new position in IDEXX Laboratories during the 3rd quarter worth $25,000. Retirement Wealth Solutions LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $31,000. Ashton Thomas Securities LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $37,000. Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $38,000. Finally, Crews Bank & Trust purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $41,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, March 7th. Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $412.40 on Thursday. The company’s fifty day moving average is $438.09 and its two-hundred day moving average is $448.02. The firm has a market capitalization of $33.54 billion, a price-to-earnings ratio of 38.65, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $550.24. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.18% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.